ustekinumab
janssen
['ustekinumab', 'crohn', 'ibd']
no differences in primary outcome of clinical response at w16 for ust iv reinduction compared to continue sc in patients with secondary lor. the power trial presented by scott lee at #ddw2023 #agalive2023 #ibd 
Celebrate life. Gastroenterologist #IBD passionate. Help others grow their abilities. https://t.co/4V0xhhdIti